About AIDS

A new HIV drug named Fuzeon became available last year, and AIDS Services of Austin will host a free dinner program on Wednesday, July 21, to explain the drug's pros and cons.

Fuzeon (enfuvirtide, known as T-20 during its trials) is a dramatic breakthrough in HIV treatment, as it is the first in a whole new class of upcoming drugs called fusion inhibitors or entry inhibitors. They block the virus from entering the T4/CD4 cells to begin with. Because they work outside the T4 cell, entry inhibitors should have few side effects.

As the first member of its class – and like any drug – Fuzeon has its challenges. Its molecule is so large and complex that it cannot be taken orally; it must be injected twice daily. Fuzeon is one of the most expensive drugs ever marketed, although that will not be noticeable to most interested patients, as it is insurance or the state/federal AIDS Drug Assistance Program that will pay for it. However, as part of a patient's treatment combination, fusion inhibitors will be a valuable addition to the drug arsenal, especially for patients for whom other drugs are no longer working well.

The July 21 program will feature a "consumers' panel" of patients and nurses who have experience with Fuzeon. Attendees will be able to learn more about how and when this drug is being used, as well as the ups and downs of taking it. The program will be beneficial for patients, care providers, and professional staff involved in HIV/AIDS work.

Dinner will be served as part of the evening program, thanks to generous sponsorship by drug manufacturer Roche Laboratories. Spanish translation will be provided. As always, generous door prizes are in store!

The program will be at ASA, 7215 Cameron (just north of St. Johns) from 6 to 8pm. To help us estimate food needs, please respond ASAP: telephone 888/839-9657; fax 866/839-4816; e-mail [email protected]; or just tell ASA's receptionist if you are in the building.